| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Aethlon Medical, Inc. (NASDAQ:AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (NASDAQ:PPD), a leading global contract research organization (CRO), for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.
Pursuant to the agreement, PPD will manage Aethlon's ongoing study of the Hemopurifier for patients who are critically ill with COVID-19 (NCT04595903). PPD and Aethlon also can agree to include additional studies under their agreement.
"Aethlon is committed to progressing the clinical development of the Hemopurifier," said Charles J. Fisher, M.D., Chief Executive Officer of Aethlon Medical. "PPD is a world class organization with significant experience operating clinical studies. Aethlon plans to move quickly to leverage this experience to advance our studies of the Hemopurifier in COVID-19 patients."
